Interestingly, the pathophysiological milieu of heart failure and diabetes mellitus is associated with an up‐regulation of SGLT2 expression in proximal renal tubules, thereby supporting the rationale for SGLT2 inhibitors as a targeted therapeutic approach.9, 10, 11. This evidence concerns the gene SLC5A2 and heart failure.